Published in TB and Outbreaks Week, September 5th, 2000
H. Furrer and colleagues, University Hospital of Bern, conducted a prospective, multicenter cohort study to determine if eliminating primary prophylaxis against disseminated MAC in HIV patients on HAART would be safe.
"HIV infected patients were eligible for the analysis if: (i) they had a history of at least two CD4 cell counts <50x106/l; (ii) they had never had MAC; (iii) they had discontinued or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.